A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis

NCT04152382 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

30

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated due to liver findings

Conditions

Psoriasis

Interventions

DRUG: LY3462817 - IV
DRUG: LY3462817 - SC
DRUG: Placebo - IV
DRUG: Placebo - SC
DRUG: LY3509754
DRUG: Placebo

Sponsor

Eli Lilly and Company